# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Illumina acquires Fluent BioSciences to enhance single-cell analysis and multiomics research. 10x Genomics faces challenges as ...
Illumina has acquired Fluent BioSciences, enhancing its single-cell analysis and multiomics capabilities. Fluent's innovati...
Stephens & Co. analyst Mason Carrico reiterates Illumina (NASDAQ:ILMN) with a Overweight and maintains $170 price target.
Citigroup analyst Patrick Donnelly upgrades Illumina (NASDAQ:ILMN) from Neutral to Buy and announces $140 price target.
RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:ILMN) with a Outperform and lowers the price target from $249 ...
Illumina spins off Grail, making Grail an independent public company. Shareholders receive one GRAIL share per six Illumina sha...